{"parse":{"title":"Bioequivalence","pageid":998103,"revid":841400746,"text":{"*":"<div class=\"mw-parser-output\"><div class=\"thumb tright\"><div class=\"thumbinner\" style=\"width:337px;\"><a href=\"/wiki/File:Bupropion_bioequivalency_comparison.svg\" class=\"image\"><img alt=\"\" src=\"//upload.wikimedia.org/wikipedia/commons/thumb/7/7d/Bupropion_bioequivalency_comparison.svg/335px-Bupropion_bioequivalency_comparison.svg.png\" width=\"335\" height=\"218\" class=\"thumbimage\" srcset=\"//upload.wikimedia.org/wikipedia/commons/thumb/7/7d/Bupropion_bioequivalency_comparison.svg/503px-Bupropion_bioequivalency_comparison.svg.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/7/7d/Bupropion_bioequivalency_comparison.svg/670px-Bupropion_bioequivalency_comparison.svg.png 2x\" data-file-width=\"1000\" data-file-height=\"650\" /></a>  <div class=\"thumbcaption\"><div class=\"magnify\"><a href=\"/wiki/File:Bupropion_bioequivalency_comparison.svg\" class=\"internal\" title=\"Enlarge\"></a></div>A bioequivalency profile comparison of 150 mg extended-release <a href=\"/wiki/Bupropion\" title=\"Bupropion\">bupropion</a> as produced by <a href=\"/wiki/Impax_Laboratories\" class=\"mw-redirect\" title=\"Impax Laboratories\">Impax Laboratories</a> for <a href=\"/wiki/Teva_Pharmaceutical_Industries\" title=\"Teva Pharmaceutical Industries\">Teva</a> and <a href=\"/wiki/Biovail\" title=\"Biovail\">Biovail</a> for <a href=\"/wiki/GlaxoSmithKline\" title=\"GlaxoSmithKline\">GlaxoSmithKline</a></div></div></div>\n<p><b>Bioequivalence</b> is a term  in <a href=\"/wiki/Pharmacokinetics\" title=\"Pharmacokinetics\">pharmacokinetics</a> used to assess the expected <a href=\"/wiki/In_vivo\" title=\"In vivo\">in vivo</a> biological equivalence of two proprietary preparations of a drug. If two products are said to be bioequivalent it means that they would be expected to be, for all intents and purposes, the same.\n</p><p>Birkett (2003) defined bioequivalence by stating that, \"two pharmaceutical products are bioequivalent if they are pharmaceutically equivalent and their <a href=\"/wiki/Bioavailability\" title=\"Bioavailability\">bioavailabilities</a> (rate and extent of availability) after administration in the same molar dose are similar to such a degree that their effects, with respect to both efficacy and safety, can be expected to be essentially the same. Pharmaceutical equivalence implies the same amount of the same active substance(s), in the same dosage form, for the same route of administration and meeting the same or comparable standards.\"<sup id=\"cite_ref-Birkett_2003_1-0\" class=\"reference\"><a href=\"#cite_note-Birkett_2003-1\">&#91;1&#93;</a></sup>\n</p><p>For <a href=\"/wiki/World_Health_Organization\" title=\"World Health Organization\">The World Health Organization</a> <a rel=\"nofollow\" class=\"external text\" href=\"http://www.who.int\">(WHO)</a> \"two pharmaceutical products are bioequivalent if they are pharmaceutically equivalent or pharmaceutical alternatives, and their bioavailabilities, in terms of rate (Cmax and tmax) and extent of absorption (area under the curve), after administration of the same molar dose under the same conditions, are similar to such a degree that their effects can be expected to be essentially the same\" <sup id=\"cite_ref-2\" class=\"reference\"><a href=\"#cite_note-2\">&#91;2&#93;</a></sup>.\n</p><p>The <a href=\"/wiki/United_States\" title=\"United States\">United States</a> <a href=\"/wiki/Food_and_Drug_Administration\" title=\"Food and Drug Administration\">Food and Drug Administration</a> (FDA) has defined bioequivalence as, \"the absence of a significant difference in the rate and extent to which the active ingredient or active moiety in pharmaceutical equivalents or pharmaceutical alternatives becomes available at the site of drug action when administered at the same molar dose under similar conditions in an appropriately designed study.\"<sup id=\"cite_ref-url_www.fda.gov_3-0\" class=\"reference\"><a href=\"#cite_note-url_www.fda.gov-3\">&#91;3&#93;</a></sup>\n</p>\n<div id=\"toc\" class=\"toc\"><input type=\"checkbox\" role=\"button\" id=\"toctogglecheckbox\" class=\"toctogglecheckbox\" style=\"display:none\" /><div class=\"toctitle\" lang=\"en\" dir=\"ltr\"><h2>Contents</h2><span class=\"toctogglespan\"><label class=\"toctogglelabel\" for=\"toctogglecheckbox\"></label></span></div>\n<ul>\n<li class=\"toclevel-1 tocsection-1\"><a href=\"#Bioequivalence\"><span class=\"tocnumber\">1</span> <span class=\"toctext\">Bioequivalence</span></a></li>\n<li class=\"toclevel-1 tocsection-2\"><a href=\"#Regulatory_definition\"><span class=\"tocnumber\">2</span> <span class=\"toctext\">Regulatory definition</span></a>\n<ul>\n<li class=\"toclevel-2 tocsection-3\"><a href=\"#The_World_Health_Organization\"><span class=\"tocnumber\">2.1</span> <span class=\"toctext\">The World Health Organization</span></a></li>\n<li class=\"toclevel-2 tocsection-4\"><a href=\"#Australia\"><span class=\"tocnumber\">2.2</span> <span class=\"toctext\">Australia</span></a></li>\n<li class=\"toclevel-2 tocsection-5\"><a href=\"#Europe\"><span class=\"tocnumber\">2.3</span> <span class=\"toctext\">Europe</span></a></li>\n<li class=\"toclevel-2 tocsection-6\"><a href=\"#United_States\"><span class=\"tocnumber\">2.4</span> <span class=\"toctext\">United States</span></a></li>\n</ul>\n</li>\n<li class=\"toclevel-1 tocsection-7\"><a href=\"#Bioequivalence_issues\"><span class=\"tocnumber\">3</span> <span class=\"toctext\">Bioequivalence issues</span></a></li>\n<li class=\"toclevel-1 tocsection-8\"><a href=\"#See_also\"><span class=\"tocnumber\">4</span> <span class=\"toctext\">See also</span></a></li>\n<li class=\"toclevel-1 tocsection-9\"><a href=\"#References\"><span class=\"tocnumber\">5</span> <span class=\"toctext\">References</span></a></li>\n<li class=\"toclevel-1 tocsection-10\"><a href=\"#External_links\"><span class=\"tocnumber\">6</span> <span class=\"toctext\">External links</span></a></li>\n</ul>\n</div>\n\n<h2><span class=\"mw-headline\" id=\"Bioequivalence\">Bioequivalence</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Bioequivalence&amp;action=edit&amp;section=1\" title=\"Edit section: Bioequivalence\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<p>In determining bioequivalence, for example, between two products such as a commercially available Brand product and a potential to-be-marketed Generic product, pharmacokinetic studies are conducted whereby each of the preparations are administered in a cross-over study to volunteer subjects, generally healthy individuals but occasionally in patients. Serum/plasma samples are obtained at regular intervals and assayed for parent drug (or occasionally metabolite) concentration. Occasionally, blood concentration levels are neither feasible or possible to compare the two products (e.g. inhaled corticosteroids), then pharmacodynamic endpoints rather than pharmacokinetic endpoints (see below) are used for comparison. For a pharmacokinetic comparison, the plasma concentration data are used to assess key pharmacokinetic parameters such as area under the curve (AUC), peak concentration (<i>C</i><sub>max</sub>), time to peak concentration (<i>T</i><sub>max</sub>), and absorption lag time (<i>t</i><sub>lag</sub>). Testing should be conducted at several different doses, especially when the drug displays non-linear pharmacokinetics.\n</p><p>In addition to data from bioequivalence studies, other data may need to be submitted to meet regulatory requirements for bioequivalence. Such evidence may include:\n</p>\n<ul><li>analytical method validation</li>\n<li><i>in vitro-in vivo</i> correlation studies (<a href=\"/wiki/IVIVC\" title=\"IVIVC\">IVIVC</a>)</li></ul>\n<h2><span class=\"mw-headline\" id=\"Regulatory_definition\">Regulatory definition</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Bioequivalence&amp;action=edit&amp;section=2\" title=\"Edit section: Regulatory definition\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<h3><span class=\"mw-headline\" id=\"The_World_Health_Organization\">The World Health Organization</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Bioequivalence&amp;action=edit&amp;section=3\" title=\"Edit section: The World Health Organization\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h3>\n<p>The World Health Organization considers two formulation bioequivalent if the 90% confidence interval for the ratio multisource (generic) product/comparator lie within 80.00-125.00% acceptance range for AUC<sub>0\u2013t</sub> and C<sub>max</sub>. For high variable finished pharmaceutical products, the applicable acceptance range for C<sub>max</sub> can be 69.84-143.19% <sup id=\"cite_ref-4\" class=\"reference\"><a href=\"#cite_note-4\">&#91;4&#93;</a></sup>.\n</p>\n<h3><span class=\"mw-headline\" id=\"Australia\">Australia</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Bioequivalence&amp;action=edit&amp;section=4\" title=\"Edit section: Australia\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h3>\n<p>In <a href=\"/wiki/Australia\" title=\"Australia\">Australia</a>, the <a href=\"/wiki/Therapeutics_Goods_Administration\" class=\"mw-redirect\" title=\"Therapeutics Goods Administration\">Therapeutics Goods Administration</a> (TGA) considers preparations to be bioequivalent if the 90% <a href=\"/wiki/Confidence_interval\" title=\"Confidence interval\">confidence intervals</a> (90% CI) of the rate ratios, between the two preparations, of <i>C</i><sub>max</sub> and AUC lie in the range 0.80\u20131.25. <i>T</i><sub>max</sub> should also be similar between the products.<sup id=\"cite_ref-Birkett_2003_1-1\" class=\"reference\"><a href=\"#cite_note-Birkett_2003-1\">&#91;1&#93;</a></sup>\n</p><p>There are tighter requirements for drugs with a narrow <a href=\"/wiki/Therapeutic_index\" title=\"Therapeutic index\">therapeutic index</a> and/or saturable metabolism &#8211; thus no generic products exist on the Australian market for <a href=\"/wiki/Digoxin\" title=\"Digoxin\">digoxin</a> or <a href=\"/wiki/Phenytoin\" title=\"Phenytoin\">phenytoin</a> for instance.\n</p>\n<h3><span class=\"mw-headline\" id=\"Europe\">Europe</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Bioequivalence&amp;action=edit&amp;section=5\" title=\"Edit section: Europe\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h3>\n<p>According to regulations applicable in the <a href=\"/wiki/European_Economic_Area\" title=\"European Economic Area\">European Economic Area</a><sup id=\"cite_ref-urlwww.emea.europa.eu_5-0\" class=\"reference\"><a href=\"#cite_note-urlwww.emea.europa.eu-5\">&#91;5&#93;</a></sup> two medicinal products are bioequivalent if they are pharmaceutically equivalent or pharmaceutical alternatives and if their bioavailabilities after administration in the same molar dose are similar to such a degree that their effects, with respect to both efficacy and safety, will be essentially the same. This is considered demonstrated if the 90% <a href=\"/wiki/Confidence_interval\" title=\"Confidence interval\">confidence intervals</a> (90% CI) of the ratios for AUC<sub>0\u2013t</sub> and <i>C</i><sub>max</sub> between the two preparations lie in the range 80\u2013125%.\n</p>\n<h3><span class=\"mw-headline\" id=\"United_States\">United States</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Bioequivalence&amp;action=edit&amp;section=6\" title=\"Edit section: United States\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h3>\n<p>The FDA considers two products bioequivalent if the 90% CI of the relative mean C<sub>max</sub>, AUC<sub>(0\u2013t)</sub> and AUC<sub>(0\u2013\u221e)</sub> of the test (e.g. generic formulation) to reference (e.g. innovator brand formulation) should be within 80% to 125% in the fasting state. Although there are a few exceptions, generally a bioequivalent comparison of Test to Reference formulations also requires administration after an appropriate meal at a specified time before taking the drug, a so-called \"fed\" or \"food-effect\" study. A food-effect study requires the same statistical evaluation as the fasting study, described above.<sup id=\"cite_ref-url_www.fda.gov_3-1\" class=\"reference\"><a href=\"#cite_note-url_www.fda.gov-3\">&#91;3&#93;</a></sup>\n</p>\n<h2><span class=\"mw-headline\" id=\"Bioequivalence_issues\">Bioequivalence issues</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Bioequivalence&amp;action=edit&amp;section=7\" title=\"Edit section: Bioequivalence issues\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<p>While the FDA maintains that approved generic drugs are equivalent to their branded counterparts, bioequivalence problems have been reported by physicians and patients for many drugs.<sup id=\"cite_ref-Midha_KK,_McKay_G_664\u201370_6-0\" class=\"reference\"><a href=\"#cite_note-Midha_KK,_McKay_G_664\u201370-6\">&#91;6&#93;</a></sup> Certain classes of drugs are suspected to be particularly problematic because of their chemistry. Some of these include chiral drugs, poorly absorbed drugs, and cytotoxic drugs. In addition, complex delivery mechanisms can cause bioequivalence variances.<sup id=\"cite_ref-Midha_KK,_McKay_G_664\u201370_6-1\" class=\"reference\"><a href=\"#cite_note-Midha_KK,_McKay_G_664\u201370-6\">&#91;6&#93;</a></sup> Physicians are cautioned to avoid switching patients from branded to generic, or between different generic manufacturers, when prescriping anti-epileptic drugs, <a href=\"/wiki/Warfarin\" title=\"Warfarin\">warfarin</a>, and <a href=\"/wiki/Levothyroxine\" title=\"Levothyroxine\">levothyroxine</a>.<sup id=\"cite_ref-cell.com_7-0\" class=\"reference\"><a href=\"#cite_note-cell.com-7\">&#91;7&#93;</a></sup>\n</p><p>Major issues were raised in the verification of bioequivalence when multiple generic versions of FDA-approved generic drug were found not to be equivalent in efficacy and side effect profiles.<sup id=\"cite_ref-8\" class=\"reference\"><a href=\"#cite_note-8\">&#91;8&#93;</a></sup> In 2007, two providers of consumer information on nutritional products and supplements, <a href=\"/wiki/ConsumerLab.com\" title=\"ConsumerLab.com\">ConsumerLab.com</a> and The People's Pharmacy, released the results of comparative tests of different brands of bupropion.<sup id=\"cite_ref-peoples_9-0\" class=\"reference\"><a href=\"#cite_note-peoples-9\">&#91;9&#93;</a></sup> The People's Pharmacy received multiple reports of increased side effects and decreased efficacy of generic bupropion, which prompted it to ask ConsumerLab.com to test the products in question. The tests showed that some generic versions of Wellbutrin XL 300&#160;mg didn't perform the same as the brand-name pill in laboratory tests.<sup id=\"cite_ref-msnbc_10-0\" class=\"reference\"><a href=\"#cite_note-msnbc-10\">&#91;10&#93;</a></sup> The FDA investigated these complaints and concluded that the generic version is equivalent to Wellbutrin XL in regard to bioavailability of bupropion and its main active metabolite hydroxybupropion. The FDA also said that coincidental natural mood variation is the most likely explanation for the apparent worsening of depression after the switch from Wellbutrin XL to Budeprion XL.<sup id=\"cite_ref-urlReview_of_Therapeutic_Equivalence:_Generic_Bupropion_XL_300&#160;mg_and_Wellbutrin_XL_300&#160;mg_11-0\" class=\"reference\"><a href=\"#cite_note-urlReview_of_Therapeutic_Equivalence:_Generic_Bupropion_XL_300_mg_and_Wellbutrin_XL_300_mg-11\">&#91;11&#93;</a></sup> After several years of denying patient reports, in 2012 the FDA reversed this opinion, announcing that \"Budeprion XL 300&#160;mg fails to demonstrate therapeutic equivalence to Wellbutrin XL 300&#160;mg.\"<sup id=\"cite_ref-PR_FDA20121023_12-0\" class=\"reference\"><a href=\"#cite_note-PR_FDA20121023-12\">&#91;12&#93;</a></sup> The FDA did not test the bioequivalence of any of the other generic versions of Wellbutrin XL 300&#160;mg, but requested that the four manufacturers submit data on this question to the FDA by March 2013. As of October 2013, the FDA has made determinations on the formulations from some manufacturers not being bioequivalent.<sup id=\"cite_ref-13\" class=\"reference\"><a href=\"#cite_note-13\">&#91;13&#93;</a></sup>\n</p><p>In 2004, <a href=\"/wiki/Ranbaxy\" class=\"mw-redirect\" title=\"Ranbaxy\">Ranbaxy</a> was revealed to have been falsifying data regarding the generic drugs they were manufacturing. As a result, 30 products were removed from US markets and Ranbaxy paid $500 million in fines. The FDA investigated many Indian drug manufacturers after this was discovered, and as a result at least 12 companies have been banned from shipping drugs to the US.<sup id=\"cite_ref-cell.com_7-1\" class=\"reference\"><a href=\"#cite_note-cell.com-7\">&#91;7&#93;</a></sup>\n</p>\n<h2><span class=\"mw-headline\" id=\"See_also\">See also</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Bioequivalence&amp;action=edit&amp;section=8\" title=\"Edit section: See also\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<ul><li><a href=\"/wiki/Generic_drug\" title=\"Generic drug\">Generic drug</a></li>\n<li><a href=\"/wiki/Pharmacokinetics\" title=\"Pharmacokinetics\">Pharmacokinetics</a></li>\n<li><a href=\"/wiki/Clinical_trial\" title=\"Clinical trial\">Clinical trial</a></li>\n<li><a href=\"/wiki/Abbreviated_New_Drug_Application\" title=\"Abbreviated New Drug Application\">Abbreviated New Drug Application</a></li></ul>\n<h2><span class=\"mw-headline\" id=\"References\">References</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Bioequivalence&amp;action=edit&amp;section=9\" title=\"Edit section: References\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<div class=\"reflist\" style=\"list-style-type: decimal;\">\n<div class=\"mw-references-wrap mw-references-columns\"><ol class=\"references\">\n<li id=\"cite_note-Birkett_2003-1\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-Birkett_2003_1-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-Birkett_2003_1-1\"><sup><i><b>b</b></i></sup></a></span> <span class=\"reference-text\"><cite class=\"citation journal\">Birkett DJ (2003). <a rel=\"nofollow\" class=\"external text\" href=\"http://www.australianprescriber.com/magazine/26/4/article/712.pdf\">\"Generics - equal or not?\"</a> <span style=\"font-size:85%;\">(PDF)</span>. <i>Aust Prescr</i>. <b>26</b>: 85\u20137. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.18773/austprescr.2003.063\">10.18773/austprescr.2003.063</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Aust+Prescr&amp;rft.atitle=Generics+-+equal+or+not%3F&amp;rft.volume=26&amp;rft.pages=85-7&amp;rft.date=2003&amp;rft_id=info%3Adoi%2F10.18773%2Faustprescr.2003.063&amp;rft.au=Birkett+DJ&amp;rft_id=http%3A%2F%2Fwww.australianprescriber.com%2Fmagazine%2F26%2F4%2Farticle%2F712.pdf&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ABioequivalence\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-2\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-2\">^</a></b></span> <span class=\"reference-text\">WHO Guidance for organizations performing in vivo bioequivalence studies. WHO Technical Report Series No. 996, 2016, Annex 9</span>\n</li>\n<li id=\"cite_note-url_www.fda.gov-3\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-url_www.fda.gov_3-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-url_www.fda.gov_3-1\"><sup><i><b>b</b></i></sup></a></span> <span class=\"reference-text\"><cite class=\"citation web\">Center for Drug Evaluation and Research (2003). <a rel=\"nofollow\" class=\"external text\" href=\"http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/AbbreviatedNewDrugApplicationANDAGenerics/UCM154838.pdf\">\"Guidance for Industry: Bioavailability and Bioequivalence Studies for Orally Administered Drug Products \u2014 General Considerations\"</a> <span style=\"font-size:85%;\">(PDF)</span>. United States Food and Drug Administration.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Guidance+for+Industry%3A+Bioavailability+and+Bioequivalence+Studies+for+Orally+Administered+Drug+Products+%E2%80%94+General+Considerations&amp;rft.pub=United+States+Food+and+Drug+Administration&amp;rft.date=2003&amp;rft.au=Center+for+Drug+Evaluation+and+Research&amp;rft_id=http%3A%2F%2Fwww.fda.gov%2Fdownloads%2FDrugs%2FDevelopmentApprovalProcess%2FHowDrugsareDevelopedandApproved%2FApprovalApplications%2FAbbreviatedNewDrugApplicationANDAGenerics%2FUCM154838.pdf&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ABioequivalence\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-4\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-4\">^</a></b></span> <span class=\"reference-text\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.who.int/medicines/areas/quality_safety/quality_assurance/trs1003_annex6.pdf?ua=1\">WHO guidelines on Multisource (generic) pharmaceutical products: guidelines on registration requirements to establish interchangeability WHO Technical Report Series, No. 1003, 2017, Annex 6</a></span>\n</li>\n<li id=\"cite_note-urlwww.emea.europa.eu-5\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-urlwww.emea.europa.eu_5-0\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\">Committee for Medicinal Products for Human Use (20 January 2010). <a rel=\"nofollow\" class=\"external text\" href=\"http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2010/01/WC500070039.pdf\">\"Guideline on the Investigation of Bioequivalence\"</a> <span style=\"font-size:85%;\">(pdf)</span>. <a href=\"/wiki/European_Medicines_Agency\" title=\"European Medicines Agency\">European Medicines Agency</a><span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">21 April</span> 2011</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Guideline+on+the+Investigation+of+Bioequivalence&amp;rft.pub=European+Medicines+Agency&amp;rft.date=2010-01-20&amp;rft.au=Committee+for+Medicinal+Products+for+Human+Use&amp;rft_id=http%3A%2F%2Fwww.ema.europa.eu%2Fdocs%2Fen_GB%2Fdocument_library%2FScientific_guideline%2F2010%2F01%2FWC500070039.pdf&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ABioequivalence\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-Midha_KK,_McKay_G_664\u201370-6\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-Midha_KK,_McKay_G_664\u201370_6-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-Midha_KK,_McKay_G_664\u201370_6-1\"><sup><i><b>b</b></i></sup></a></span> <span class=\"reference-text\"><cite class=\"citation journal\">Midha KK, McKay G. <a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pmc/articles/PMC2782076\">\"Bioequivalence; its history, practice, and future\"</a>. <i>AAPS J</i>. <b>11</b>: 664\u201370. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1208/s12248-009-9142-z\">10.1208/s12248-009-9142-z</a>. <a href=\"/wiki/PubMed_Central\" title=\"PubMed Central\">PMC</a>&#160;<span class=\"plainlinks\"><a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pmc/articles/PMC2782076\">2782076</a>&#8239;<img alt=\"Freely accessible\" src=\"//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png\" title=\"Freely accessible\" width=\"9\" height=\"14\" srcset=\"//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/14px-Lock-green.svg.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/18px-Lock-green.svg.png 2x\" data-file-width=\"512\" data-file-height=\"813\" /></span>. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/19806461\">19806461</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=AAPS+J&amp;rft.atitle=Bioequivalence%3B+its+history%2C+practice%2C+and+future&amp;rft.volume=11&amp;rft.pages=664-70&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC2782076&amp;rft_id=info%3Apmid%2F19806461&amp;rft_id=info%3Adoi%2F10.1208%2Fs12248-009-9142-z&amp;rft.au=Midha+KK%2C+McKay+G&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC2782076&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ABioequivalence\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-cell.com-7\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-cell.com_7-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-cell.com_7-1\"><sup><i><b>b</b></i></sup></a></span> <span class=\"reference-text\"><a rel=\"nofollow\" class=\"external free\" href=\"http://www.cell.com/trends/pharmacological-sciences/fulltext/S0165-6147(15)00241-2\">http://www.cell.com/trends/pharmacological-sciences/fulltext/S0165-6147(15)00241-2</a></span>\n</li>\n<li id=\"cite_note-8\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-8\">^</a></b></span> <span class=\"reference-text\"><a rel=\"nofollow\" class=\"external free\" href=\"http://www.raps.org/focus-online/news/news-article-view/article/3794/\">http://www.raps.org/focus-online/news/news-article-view/article/3794/</a></span>\n</li>\n<li id=\"cite_note-peoples-9\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-peoples_9-0\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.peoplespharmacy.com/archives/generic_drug_problems/generic_drug_equality_questioned.php\">\"Generic drug equality questioned\"</a><span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">13 October</span> 2007</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Generic+drug+equality+questioned&amp;rft_id=http%3A%2F%2Fwww.peoplespharmacy.com%2Farchives%2Fgeneric_drug_problems%2Fgeneric_drug_equality_questioned.php&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ABioequivalence\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-msnbc-10\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-msnbc_10-0\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\">Stenson, Jacqueline (12 October 2007). <a rel=\"nofollow\" class=\"external text\" href=\"http://www.msnbc.msn.com/id/21142869/\">\"Report questions generic antidepressant\"</a>. <a href=\"/wiki/Msnbc.com\" class=\"mw-redirect\" title=\"Msnbc.com\">msnbc.com</a><span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">13 October</span> 2007</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Report+questions+generic+antidepressant&amp;rft.pub=msnbc.com&amp;rft.date=2007-10-12&amp;rft.au=Stenson%2C+Jacqueline&amp;rft_id=http%3A%2F%2Fwww.msnbc.msn.com%2Fid%2F21142869%2F&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ABioequivalence\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-urlReview_of_Therapeutic_Equivalence:_Generic_Bupropion_XL_300&#160;mg_and_Wellbutrin_XL_300&#160;mg-11\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-urlReview_of_Therapeutic_Equivalence:_Generic_Bupropion_XL_300_mg_and_Wellbutrin_XL_300_mg_11-0\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"https://web.archive.org/web/20110606092603/http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm153270.htm\">\"Review of therapeutic equivalence: generic bupropion XL 300&#160;mg and Wellbutrin XL 300&#160;mg\"</a>. Archived from <a rel=\"nofollow\" class=\"external text\" href=\"http://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDER/ucm153270.htm\">the original</a> on 6 June 2011<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">19 April</span> 2008</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Review+of+therapeutic+equivalence%3A+generic+bupropion+XL+300+mg+and+Wellbutrin+XL+300+mg&amp;rft_id=http%3A%2F%2Fwww.fda.gov%2FAboutFDA%2FCentersOffices%2FOfficeofMedicalProductsandTobacco%2FCDER%2Fucm153270.htm&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ABioequivalence\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-PR_FDA20121023-12\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-PR_FDA20121023_12-0\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation pressrelease\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm322161.htm\">\"Budeprion XL 300&#160;mg not therapeutically equivalent to Wellbutrin XL 300&#160;mg\"</a> (Press release). FDA. 3 October 2012<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">23 March</span> 2013</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Budeprion+XL+300+mg+not+therapeutically+equivalent+to+Wellbutrin+XL+300+mg&amp;rft.pub=FDA&amp;rft.date=2012-10-03&amp;rft_id=http%3A%2F%2Fwww.fda.gov%2FDrugs%2FDrugSafety%2FPostmarketDrugSafetyInformationforPatientsandProviders%2Fucm322161.htm&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ABioequivalence\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-13\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-13\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.fda.gov/drugs/drugsafety/postmarketdrugsafetyinformationforpatientsandproviders/ucm322161.htm\">\"FDA Update\"</a>. FDA. October 2013<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">15 June</span> 2015</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=FDA+Update&amp;rft.pub=FDA&amp;rft.date=2013-10&amp;rft_id=http%3A%2F%2Fwww.fda.gov%2Fdrugs%2Fdrugsafety%2Fpostmarketdrugsafetyinformationforpatientsandproviders%2Fucm322161.htm&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ABioequivalence\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n</ol></div></div>\n<h2><span class=\"mw-headline\" id=\"External_links\">External links</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Bioequivalence&amp;action=edit&amp;section=10\" title=\"Edit section: External links\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<ul><li>Hussain AS, et al. <a rel=\"nofollow\" class=\"external text\" href=\"http://www.dissolutiontech.com/DTresour/599articles/Biopharm_Class2_copy.html\">The Biopharmaceutics Classification System: Highlights of the FDA's Draft Guidance</a> Office of Pharmaceutical Science, Center for Drug Evaluation and Research, Food and Drug Administration.</li>\n<li>Mills D (2005). <a rel=\"nofollow\" class=\"external text\" href=\"https://web.archive.org/web/20051103203712/http://www.ibpassociation.org/clintrials.html\">Regulatory Agencies Do Not Require Clinical Trials To Be Expensive</a> International Biopharmaceutical Association: IBPA Publications.</li>\n<li><a rel=\"nofollow\" class=\"external text\" href=\"https://web.archive.org/web/20110318232534/http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm119100.htm\">FDA CDER Office of Generic Drugs</a> &#8211; further U.S. information on bioequivalence testing and generic drugs</li>\n<li><a rel=\"nofollow\" class=\"external text\" href=\"http://www.who.int/medicines/areas/quality_safety/quality_assurance/ProposalWaiveVivoBioequivalenceRequirementsModelListEssentialMedicinesImmediateReleaseSolidOralDosageFormsTRS937Annex8.pdf?ua=1\">Proposal to waive in vivo bioequivalence requirements for WHO Model List of Essential Medicines immediate-release, solid oral dosage forms</a>. WHO Technical Report Series, No. 937, 2006, Annex 8.</li>\n<li><a rel=\"nofollow\" class=\"external text\" href=\"http://www.who.int/medicines/publications/pharmprep/WHO_TRS_996_annex09.pdf?ua=1\">Guidance for organizations performing in vivo bioequivalence studies (revision)</a>. WHO Technical Report Series 996, 2016, Annex 9.</li>\n<li><a rel=\"nofollow\" class=\"external text\" href=\"http://www.who.int/medicines/areas/quality_safety/quality_assurance/Annex5.pdf?ua=1\">General background notes and list of international comparator pharmaceutical products</a>. WHO Technical Report Series 1003, 2017, Annex 5.</li>\n<li><a rel=\"nofollow\" class=\"external text\" href=\"http://www.who.int/medicines/areas/quality_safety/quality_assurance/regulatory_standards/en/\">WHO List of International Comparator products</a> (September 2016)</li></ul>\n<div role=\"navigation\" class=\"navbox\" aria-labelledby=\"Concepts_in_pharmacology\" style=\"padding:3px\"><table class=\"nowraplinks collapsible autocollapse navbox-inner\" style=\"border-spacing:0;background:transparent;color:inherit\"><tbody><tr><th scope=\"col\" class=\"navbox-title\" colspan=\"2\" style=\"background:#efefef\"><div class=\"plainlinks hlist navbar mini\"><ul><li class=\"nv-view\"><a href=\"/wiki/Template:Pharmacology\" title=\"Template:Pharmacology\"><abbr title=\"View this template\" style=\";background:#efefef;background:none transparent;border:none;-moz-box-shadow:none;-webkit-box-shadow:none;box-shadow:none; padding:0;\">v</abbr></a></li><li class=\"nv-talk\"><a href=\"/wiki/Template_talk:Pharmacology\" title=\"Template talk:Pharmacology\"><abbr title=\"Discuss this template\" style=\";background:#efefef;background:none transparent;border:none;-moz-box-shadow:none;-webkit-box-shadow:none;box-shadow:none; padding:0;\">t</abbr></a></li><li class=\"nv-edit\"><a class=\"external text\" href=\"//en.wikipedia.org/w/index.php?title=Template:Pharmacology&amp;action=edit\"><abbr title=\"Edit this template\" style=\";background:#efefef;background:none transparent;border:none;-moz-box-shadow:none;-webkit-box-shadow:none;box-shadow:none; padding:0;\">e</abbr></a></li></ul></div><div id=\"Concepts_in_pharmacology\" style=\"font-size:114%;margin:0 4em\">Concepts in <a href=\"/wiki/Pharmacology\" title=\"Pharmacology\">pharmacology</a></div></th></tr><tr><th scope=\"row\" class=\"navbox-group\" style=\"width:1%\"><a href=\"/wiki/Pharmacokinetics\" title=\"Pharmacokinetics\">Pharmacokinetics</a></th><td class=\"navbox-list navbox-odd hlist\" style=\"text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px\"><div style=\"padding:0em 0.25em\">\n<ul><li><a href=\"/wiki/ADME\" title=\"ADME\">(L)ADME</a>: (<a href=\"/wiki/Liberation_(pharmacology)\" title=\"Liberation (pharmacology)\">Liberation</a>)</li>\n<li><a href=\"/wiki/Absorption_(pharmacokinetics)\" class=\"mw-redirect\" title=\"Absorption (pharmacokinetics)\">Absorption</a></li>\n<li><a href=\"/wiki/Distribution_(pharmacology)\" title=\"Distribution (pharmacology)\">Distribution</a></li>\n<li><a href=\"/wiki/Drug_metabolism\" title=\"Drug metabolism\">Metabolism</a></li>\n<li><a href=\"/wiki/Excretion\" title=\"Excretion\">Excretion</a> (<a href=\"/wiki/Clearance_(medicine)\" class=\"mw-redirect\" title=\"Clearance (medicine)\">Clearance</a>)</li></ul>\n<ul><li><a href=\"/wiki/Loading_dose\" title=\"Loading dose\">Loading dose</a></li>\n<li><a href=\"/wiki/Volume_of_distribution\" title=\"Volume of distribution\">Volume of distribution</a> (<a href=\"/wiki/Initial_volume_of_distribution\" title=\"Initial volume of distribution\">Initial</a>)</li>\n<li><a href=\"/wiki/Rate_of_infusion\" title=\"Rate of infusion\">Rate of infusion</a></li></ul>\n<ul><li><a href=\"/wiki/Compartment_(pharmacokinetics)\" title=\"Compartment (pharmacokinetics)\">Compartment</a></li>\n<li><a class=\"mw-selflink selflink\">Bioequivalence</a></li>\n<li><a href=\"/wiki/Bioavailability\" title=\"Bioavailability\">Bioavailability</a></li></ul>\n<ul><li><a href=\"/wiki/Onset_of_action\" title=\"Onset of action\">Onset of action</a></li>\n<li><a href=\"/wiki/Biological_half-life\" title=\"Biological half-life\">Biological half-life</a></li>\n<li><a href=\"/wiki/Plasma_protein_binding\" title=\"Plasma protein binding\">Plasma protein binding</a></li></ul>\n</div></td></tr><tr><th scope=\"row\" class=\"navbox-group\" style=\"width:1%\"><a href=\"/wiki/Pharmacodynamics\" title=\"Pharmacodynamics\">Pharmacodynamics</a></th><td class=\"navbox-list navbox-even hlist\" style=\"text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px\"><div style=\"padding:0em 0.25em\">\n<ul><li><a href=\"/wiki/Mechanism_of_action\" title=\"Mechanism of action\">Mechanism of action</a></li>\n<li><a href=\"/wiki/Mode_of_action\" title=\"Mode of action\">Mode of action</a></li>\n<li><a href=\"/wiki/Toxicity\" title=\"Toxicity\">Toxicity</a> (<a href=\"/wiki/Neurotoxicology\" class=\"mw-redirect\" title=\"Neurotoxicology\">Neurotoxicology</a>)</li>\n<li><a href=\"/wiki/Dose%E2%80%93response_relationship\" title=\"Dose\u2013response relationship\">Dose\u2013response relationship</a> (<a href=\"/wiki/Efficacy#Pharmacology\" title=\"Efficacy\">Efficacy</a>, <a href=\"/wiki/Potency_(pharmacology)\" title=\"Potency (pharmacology)\">Potency</a>)</li>\n<li><a href=\"/wiki/Therapeutic_index\" title=\"Therapeutic index\">Therapeutic index</a> (<a href=\"/wiki/Median_lethal_dose\" title=\"Median lethal dose\">Median lethal dose</a>, <a href=\"/wiki/Effective_dose_(pharmacology)\" title=\"Effective dose (pharmacology)\">Effective dose</a>)</li></ul>\n<ul><li><a href=\"/wiki/Antimicrobial_pharmacodynamics\" title=\"Antimicrobial pharmacodynamics\">Antimicrobial pharmacodynamics</a>: <a href=\"/wiki/Minimum_inhibitory_concentration\" title=\"Minimum inhibitory concentration\">Minimum inhibitory concentration</a> (<a href=\"/wiki/Bacteriostatic_agent\" title=\"Bacteriostatic agent\">Bacteriostatic</a>)</li>\n<li><a href=\"/wiki/Minimum_bactericidal_concentration\" title=\"Minimum bactericidal concentration\">Minimum bactericidal concentration</a> (<a href=\"/wiki/Bactericide\" title=\"Bactericide\">Bactericide</a>)</li></ul>\n</div></td></tr><tr><th scope=\"row\" class=\"navbox-group\" style=\"width:1%\">Agonism and<br /> antagonism</th><td class=\"navbox-list navbox-odd hlist\" style=\"text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px\"><div style=\"padding:0em 0.25em\">\n<ul><li><a href=\"/wiki/Agonist\" title=\"Agonist\">Agonist</a>: <a href=\"/wiki/Inverse_agonist\" title=\"Inverse agonist\">Inverse agonist</a></li>\n<li><a href=\"/wiki/Irreversible_agonist\" title=\"Irreversible agonist\">Irreversible agonist</a></li>\n<li><a href=\"/wiki/Partial_agonist\" title=\"Partial agonist\">Partial agonist</a></li>\n<li><a href=\"/wiki/Superagonist\" title=\"Superagonist\">Superagonist</a></li>\n<li><a href=\"/wiki/Physiological_agonism_and_antagonism\" title=\"Physiological agonism and antagonism\">Physiological agonist</a></li></ul>\n<ul><li><a href=\"/wiki/Receptor_antagonist\" title=\"Receptor antagonist\">Antagonist</a>: <a href=\"/wiki/Competitive_antagonist\" class=\"mw-redirect\" title=\"Competitive antagonist\">Competitive antagonist</a></li>\n<li><a href=\"/wiki/Irreversible_antagonist\" title=\"Irreversible antagonist\">Irreversible antagonist</a></li>\n<li><a href=\"/wiki/Physiological_agonism_and_antagonism\" title=\"Physiological agonism and antagonism\">Physiological antagonist</a></li></ul>\n<ul><li>Other: <a href=\"/wiki/Molecular_binding\" title=\"Molecular binding\">Binding</a></li>\n<li><a href=\"/wiki/Dissociation_constant#Protein-ligand_binding\" title=\"Dissociation constant\">Affinity</a></li>\n<li><a href=\"/wiki/Binding_selectivity\" title=\"Binding selectivity\">Binding selectivity</a></li>\n<li><a href=\"/wiki/Functional_selectivity\" title=\"Functional selectivity\">Functional selectivity</a></li></ul>\n</div></td></tr><tr><th scope=\"row\" class=\"navbox-group\" style=\"width:1%\">Other</th><td class=\"navbox-list navbox-even hlist\" style=\"text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px\"><div style=\"padding:0em 0.25em\">\n<ul><li><a href=\"/wiki/Drug_tolerance\" title=\"Drug tolerance\">Drug tolerance</a>: <a href=\"/wiki/Tachyphylaxis\" title=\"Tachyphylaxis\">Tachyphylaxis</a></li></ul>\n<ul><li><a href=\"/wiki/Drug_resistance\" title=\"Drug resistance\">Drug resistance</a>: <a href=\"/wiki/Antibiotic_resistance\" class=\"mw-redirect\" title=\"Antibiotic resistance\">Antibiotic resistance</a></li>\n<li><a href=\"/wiki/Multiple_drug_resistance\" title=\"Multiple drug resistance\">Multiple drug resistance</a></li></ul>\n</div></td></tr><tr><th scope=\"row\" class=\"navbox-group\" style=\"width:1%\"><a href=\"/wiki/Drug_discovery\" title=\"Drug discovery\">Drug discovery</a><br /> strategies</th><td class=\"navbox-list navbox-odd hlist\" style=\"text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px\"><div style=\"padding:0em 0.25em\">\n<ul><li><a href=\"/wiki/Classical_pharmacology\" title=\"Classical pharmacology\">Classical pharmacology</a></li></ul>\n<ul><li><a href=\"/wiki/Reverse_pharmacology\" title=\"Reverse pharmacology\">Reverse pharmacology</a></li></ul>\n</div></td></tr><tr><th scope=\"row\" class=\"navbox-group\" style=\"width:1%\">Related<br /> fields/subfields</th><td class=\"navbox-list navbox-even hlist\" style=\"text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px\"><div style=\"padding:0em 0.25em\">\n<ul><li><a href=\"/wiki/Pharmacogenetics\" title=\"Pharmacogenetics\">Pharmacogenetics</a></li>\n<li><a href=\"/wiki/Pharmacogenomics\" title=\"Pharmacogenomics\">Pharmacogenomics</a></li></ul>\n<ul><li><a href=\"/wiki/Neuropsychopharmacology\" title=\"Neuropsychopharmacology\">Neuropsychopharmacology</a> (<a href=\"/wiki/Neuropharmacology\" title=\"Neuropharmacology\">Neuropharmacology</a>, <a href=\"/wiki/Psychopharmacology\" title=\"Psychopharmacology\">Psychopharmacology</a>)</li></ul>\n</div></td></tr></tbody></table></div>\n<p class=\"mw-empty-elt\">\n</p>\n<!-- \nNewPP limit report\nParsed by mw2198\nCached time: 20180913075840\nCache expiry: 1900800\nDynamic content: false\nCPU time usage: 0.148 seconds\nReal time usage: 0.210 seconds\nPreprocessor visited node count: 652/1000000\nPreprocessor generated node count: 0/1500000\nPost\u2010expand include size: 30229/2097152 bytes\nTemplate argument size: 172/2097152 bytes\nHighest expansion depth: 12/40\nExpensive parser function count: 1/500\nUnstrip recursion depth: 0/20\nUnstrip post\u2010expand size: 14541/5000000 bytes\nNumber of Wikibase entities loaded: 0/400\nLua time usage: 0.056/10.000 seconds\nLua memory usage: 2.71 MB/50 MB\n-->\n<!--\nTransclusion expansion time report (%,ms,calls,template)\n100.00%  152.370      1 -total\n 76.30%  116.265      1 Template:Reflist\n 30.05%   45.782      2 Template:Cite_journal\n 16.49%   25.122      6 Template:Cite_web\n 13.25%   20.189      1 Template:Use_dmy_dates\n 10.78%   16.422      1 Template:DMCA\n 10.32%   15.723      1 Template:Pharmacology\n  8.18%   12.457      1 Template:Navbox\n  6.28%    9.566      1 Template:Dated_maintenance_category\n  3.69%    5.620      1 Template:FULLROOTPAGENAME\n-->\n\n<!-- Saved in parser cache with key enwiki:pcache:idhash:998103-0!canonical and timestamp 20180913075840 and revision id 841400746\n -->\n</div>"},"langlinks":[{"lang":"ar","url":"https://ar.wikipedia.org/wiki/%D8%AA%D9%83%D8%A7%D9%81%D8%A4_%D8%AD%D9%8A%D9%88%D9%8A","langname":"Arabic","autonym":"\u0627\u0644\u0639\u0631\u0628\u064a\u0629","*":"\u062a\u0643\u0627\u0641\u0624 \u062d\u064a\u0648\u064a"},{"lang":"ca","url":"https://ca.wikipedia.org/wiki/Bioequival%C3%A8ncia","langname":"Catalan","autonym":"catal\u00e0","*":"Bioequival\u00e8ncia"},{"lang":"de","url":"https://de.wikipedia.org/wiki/Bio%C3%A4quivalenz","langname":"German","autonym":"Deutsch","*":"Bio\u00e4quivalenz"},{"lang":"es","url":"https://es.wikipedia.org/wiki/Bioequivalencia","langname":"Spanish","autonym":"espa\u00f1ol","*":"Bioequivalencia"},{"lang":"fr","url":"https://fr.wikipedia.org/wiki/Bio%C3%A9quivalence","langname":"French","autonym":"fran\u00e7ais","*":"Bio\u00e9quivalence"},{"lang":"ko","url":"https://ko.wikipedia.org/wiki/%EC%83%9D%EB%AC%BC%ED%95%99%EC%A0%81_%EB%8F%99%EB%93%B1%EC%84%B1_%EC%8B%A4%ED%97%98","langname":"Korean","autonym":"\ud55c\uad6d\uc5b4","*":"\uc0dd\ubb3c\ud559\uc801 \ub3d9\ub4f1\uc131 \uc2e4\ud5d8"},{"lang":"it","url":"https://it.wikipedia.org/wiki/Bioequivalenza","langname":"Italian","autonym":"italiano","*":"Bioequivalenza"},{"lang":"nl","url":"https://nl.wikipedia.org/wiki/Bio-equivalentie","langname":"Dutch","autonym":"Nederlands","*":"Bio-equivalentie"},{"lang":"pt","url":"https://pt.wikipedia.org/wiki/Bioequival%C3%AAncia","langname":"Portuguese","autonym":"portugu\u00eas","*":"Bioequival\u00eancia"},{"lang":"ru","url":"https://ru.wikipedia.org/wiki/%D0%91%D0%B8%D0%BE%D1%8D%D0%BA%D0%B2%D0%B8%D0%B2%D0%B0%D0%BB%D0%B5%D0%BD%D1%82%D0%BD%D0%BE%D1%81%D1%82%D1%8C","langname":"Russian","autonym":"\u0440\u0443\u0441\u0441\u043a\u0438\u0439","*":"\u0411\u0438\u043e\u044d\u043a\u0432\u0438\u0432\u0430\u043b\u0435\u043d\u0442\u043d\u043e\u0441\u0442\u044c"},{"lang":"sr","url":"https://sr.wikipedia.org/wiki/Bioekvivalentnost","langname":"Serbian","autonym":"\u0441\u0440\u043f\u0441\u043a\u0438 / srpski","*":"Bioekvivalentnost"},{"lang":"sh","url":"https://sh.wikipedia.org/wiki/Bioekvivalentnost","langname":"Serbo-Croatian","autonym":"srpskohrvatski / \u0441\u0440\u043f\u0441\u043a\u043e\u0445\u0440\u0432\u0430\u0442\u0441\u043a\u0438","*":"Bioekvivalentnost"},{"lang":"fi","url":"https://fi.wikipedia.org/wiki/Bioekvivalenssi","langname":"Finnish","autonym":"suomi","*":"Bioekvivalenssi"},{"lang":"sv","url":"https://sv.wikipedia.org/wiki/Bioekvivalens","langname":"Swedish","autonym":"svenska","*":"Bioekvivalens"},{"lang":"uk","url":"https://uk.wikipedia.org/wiki/%D0%91%D1%96%D0%BE%D0%B5%D0%BA%D0%B2%D1%96%D0%B2%D0%B0%D0%BB%D0%B5%D0%BD%D1%82%D0%BD%D1%96%D1%81%D1%82%D1%8C","langname":"Ukrainian","autonym":"\u0443\u043a\u0440\u0430\u0457\u043d\u0441\u044c\u043a\u0430","*":"\u0411\u0456\u043e\u0435\u043a\u0432\u0456\u0432\u0430\u043b\u0435\u043d\u0442\u043d\u0456\u0441\u0442\u044c"}],"categories":[{"sortkey":"","hidden":"","*":"Use_dmy_dates_from_May_2011"},{"sortkey":"","*":"Pharmacokinetics"},{"sortkey":"","*":"Clinical_research"},{"sortkey":"","*":"Life_sciences_industry"}],"links":[{"ns":14,"exists":"","*":"Category:Use dmy dates from May 2011"},{"ns":10,"exists":"","*":"Template:Pharmacology"},{"ns":0,"exists":"","*":"ADME"},{"ns":0,"exists":"","*":"Abbreviated New Drug Application"},{"ns":0,"exists":"","*":"Absorption (pharmacokinetics)"},{"ns":0,"exists":"","*":"Agonist"},{"ns":0,"exists":"","*":"Antibiotic resistance"},{"ns":0,"exists":"","*":"Antimicrobial pharmacodynamics"},{"ns":0,"exists":"","*":"Australia"},{"ns":0,"exists":"","*":"Bactericide"},{"ns":0,"exists":"","*":"Bacteriostatic agent"},{"ns":0,"exists":"","*":"Binding selectivity"},{"ns":0,"exists":"","*":"Bioavailability"},{"ns":0,"exists":"","*":"Biological half-life"},{"ns":0,"exists":"","*":"Biovail"},{"ns":0,"exists":"","*":"Bupropion"},{"ns":0,"exists":"","*":"Classical pharmacology"},{"ns":0,"exists":"","*":"Clearance (medicine)"},{"ns":0,"exists":"","*":"Clinical trial"},{"ns":0,"exists":"","*":"Compartment (pharmacokinetics)"},{"ns":0,"exists":"","*":"Competitive antagonist"},{"ns":0,"exists":"","*":"Confidence interval"},{"ns":0,"exists":"","*":"ConsumerLab.com"},{"ns":0,"exists":"","*":"Digital object identifier"},{"ns":0,"exists":"","*":"Digoxin"},{"ns":0,"exists":"","*":"Dissociation constant"},{"ns":0,"exists":"","*":"Distribution (pharmacology)"},{"ns":0,"exists":"","*":"Dose\u2013response relationship"},{"ns":0,"exists":"","*":"Drug discovery"},{"ns":0,"exists":"","*":"Drug metabolism"},{"ns":0,"exists":"","*":"Drug resistance"},{"ns":0,"exists":"","*":"Drug tolerance"},{"ns":0,"exists":"","*":"Effective dose (pharmacology)"},{"ns":0,"exists":"","*":"Efficacy"},{"ns":0,"exists":"","*":"European Economic Area"},{"ns":0,"exists":"","*":"European Medicines Agency"},{"ns":0,"exists":"","*":"Excretion"},{"ns":0,"exists":"","*":"Food and Drug Administration"},{"ns":0,"exists":"","*":"Functional selectivity"},{"ns":0,"exists":"","*":"Generic drug"},{"ns":0,"exists":"","*":"GlaxoSmithKline"},{"ns":0,"exists":"","*":"IVIVC"},{"ns":0,"exists":"","*":"Impax Laboratories"},{"ns":0,"exists":"","*":"In vivo"},{"ns":0,"exists":"","*":"Initial volume of distribution"},{"ns":0,"exists":"","*":"Inverse agonist"},{"ns":0,"exists":"","*":"Irreversible agonist"},{"ns":0,"exists":"","*":"Irreversible antagonist"},{"ns":0,"exists":"","*":"Levothyroxine"},{"ns":0,"exists":"","*":"Liberation (pharmacology)"},{"ns":0,"exists":"","*":"Loading dose"},{"ns":0,"exists":"","*":"Mechanism of action"},{"ns":0,"exists":"","*":"Median lethal dose"},{"ns":0,"exists":"","*":"Minimum bactericidal concentration"},{"ns":0,"exists":"","*":"Minimum inhibitory concentration"},{"ns":0,"exists":"","*":"Mode of action"},{"ns":0,"exists":"","*":"Molecular binding"},{"ns":0,"exists":"","*":"Msnbc.com"},{"ns":0,"exists":"","*":"Multiple drug resistance"},{"ns":0,"exists":"","*":"Neuropharmacology"},{"ns":0,"exists":"","*":"Neuropsychopharmacology"},{"ns":0,"exists":"","*":"Neurotoxicology"},{"ns":0,"exists":"","*":"Onset of action"},{"ns":0,"exists":"","*":"Partial agonist"},{"ns":0,"exists":"","*":"Pharmacodynamics"},{"ns":0,"exists":"","*":"Pharmacogenetics"},{"ns":0,"exists":"","*":"Pharmacogenomics"},{"ns":0,"exists":"","*":"Pharmacokinetics"},{"ns":0,"exists":"","*":"Pharmacology"},{"ns":0,"exists":"","*":"Phenytoin"},{"ns":0,"exists":"","*":"Physiological agonism and antagonism"},{"ns":0,"exists":"","*":"Plasma protein binding"},{"ns":0,"exists":"","*":"Potency (pharmacology)"},{"ns":0,"exists":"","*":"Psychopharmacology"},{"ns":0,"exists":"","*":"PubMed Central"},{"ns":0,"exists":"","*":"PubMed Identifier"},{"ns":0,"exists":"","*":"Ranbaxy"},{"ns":0,"exists":"","*":"Rate of infusion"},{"ns":0,"exists":"","*":"Receptor antagonist"},{"ns":0,"exists":"","*":"Reverse pharmacology"},{"ns":0,"exists":"","*":"Superagonist"},{"ns":0,"exists":"","*":"Tachyphylaxis"},{"ns":0,"exists":"","*":"Teva Pharmaceutical Industries"},{"ns":0,"exists":"","*":"Therapeutic index"},{"ns":0,"exists":"","*":"Therapeutics Goods Administration"},{"ns":0,"exists":"","*":"Toxicity"},{"ns":0,"exists":"","*":"United States"},{"ns":0,"exists":"","*":"Volume of distribution"},{"ns":0,"exists":"","*":"Warfarin"},{"ns":0,"exists":"","*":"World Health Organization"},{"ns":11,"exists":"","*":"Template talk:Pharmacology"}],"templates":[{"ns":10,"exists":"","*":"Template:Reflist"},{"ns":10,"exists":"","*":"Template:Cite journal"},{"ns":10,"exists":"","*":"Template:Cite web"},{"ns":10,"exists":"","*":"Template:Cite press release"},{"ns":10,"exists":"","*":"Template:Main other"},{"ns":10,"exists":"","*":"Template:Pharmacology"},{"ns":10,"exists":"","*":"Template:Navbox"},{"ns":10,"exists":"","*":"Template:Use dmy dates"},{"ns":10,"exists":"","*":"Template:DMCA"},{"ns":10,"exists":"","*":"Template:Dated maintenance category"},{"ns":10,"exists":"","*":"Template:FULLROOTPAGENAME"},{"ns":10,"exists":"","*":"Template:Ns has subpages"},{"ns":828,"exists":"","*":"Module:Citation/CS1"},{"ns":828,"exists":"","*":"Module:Citation/CS1/Configuration"},{"ns":828,"exists":"","*":"Module:Citation/CS1/Whitelist"},{"ns":828,"exists":"","*":"Module:Citation/CS1/Utilities"},{"ns":828,"exists":"","*":"Module:Citation/CS1/Date validation"},{"ns":828,"exists":"","*":"Module:Citation/CS1/Identifiers"},{"ns":828,"exists":"","*":"Module:Citation/CS1/COinS"},{"ns":828,"exists":"","*":"Module:Check for unknown parameters"},{"ns":828,"exists":"","*":"Module:Navbox"},{"ns":828,"exists":"","*":"Module:Navbar"},{"ns":828,"exists":"","*":"Module:Arguments"},{"ns":828,"exists":"","*":"Module:Unsubst"},{"ns":828,"exists":"","*":"Module:Ns has subpages"}],"images":["Lock-green.svg","Bupropion_bioequivalency_comparison.svg"],"externallinks":["http://www.australianprescriber.com/magazine/26/4/article/712.pdf","//doi.org/10.18773/austprescr.2003.063","http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/AbbreviatedNewDrugApplicationANDAGenerics/UCM154838.pdf","http://www.who.int/medicines/areas/quality_safety/quality_assurance/trs1003_annex6.pdf?ua=1","http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2010/01/WC500070039.pdf","//www.ncbi.nlm.nih.gov/pmc/articles/PMC2782076","//doi.org/10.1208/s12248-009-9142-z","//www.ncbi.nlm.nih.gov/pubmed/19806461","http://www.peoplespharmacy.com/archives/generic_drug_problems/generic_drug_equality_questioned.php","http://www.msnbc.msn.com/id/21142869/","https://web.archive.org/web/20110606092603/http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm153270.htm","http://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDER/ucm153270.htm","http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm322161.htm","http://www.fda.gov/drugs/drugsafety/postmarketdrugsafetyinformationforpatientsandproviders/ucm322161.htm","http://www.cell.com/trends/pharmacological-sciences/fulltext/S0165-6147(15)00241-2","http://www.raps.org/focus-online/news/news-article-view/article/3794/","http://www.who.int","http://www.dissolutiontech.com/DTresour/599articles/Biopharm_Class2_copy.html","https://web.archive.org/web/20051103203712/http://www.ibpassociation.org/clintrials.html","https://web.archive.org/web/20110318232534/http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm119100.htm","http://www.who.int/medicines/areas/quality_safety/quality_assurance/ProposalWaiveVivoBioequivalenceRequirementsModelListEssentialMedicinesImmediateReleaseSolidOralDosageFormsTRS937Annex8.pdf?ua=1","http://www.who.int/medicines/publications/pharmprep/WHO_TRS_996_annex09.pdf?ua=1","http://www.who.int/medicines/areas/quality_safety/quality_assurance/Annex5.pdf?ua=1","http://www.who.int/medicines/areas/quality_safety/quality_assurance/regulatory_standards/en/"],"sections":[{"toclevel":1,"level":"2","line":"Bioequivalence","number":"1","index":"1","fromtitle":"Bioequivalence","byteoffset":3054,"anchor":"Bioequivalence"},{"toclevel":1,"level":"2","line":"Regulatory definition","number":"2","index":"2","fromtitle":"Bioequivalence","byteoffset":4457,"anchor":"Regulatory_definition"},{"toclevel":2,"level":"3","line":"The World Health Organization","number":"2.1","index":"3","fromtitle":"Bioequivalence","byteoffset":4486,"anchor":"The_World_Health_Organization"},{"toclevel":2,"level":"3","line":"Australia","number":"2.2","index":"4","fromtitle":"Bioequivalence","byteoffset":5188,"anchor":"Australia"},{"toclevel":2,"level":"3","line":"Europe","number":"2.3","index":"5","fromtitle":"Bioequivalence","byteoffset":5779,"anchor":"Europe"},{"toclevel":2,"level":"3","line":"United States","number":"2.4","index":"6","fromtitle":"Bioequivalence","byteoffset":6788,"anchor":"United_States"},{"toclevel":1,"level":"2","line":"Bioequivalence issues","number":"3","index":"7","fromtitle":"Bioequivalence","byteoffset":7469,"anchor":"Bioequivalence_issues"},{"toclevel":1,"level":"2","line":"See also","number":"4","index":"8","fromtitle":"Bioequivalence","byteoffset":12122,"anchor":"See_also"},{"toclevel":1,"level":"2","line":"References","number":"5","index":"9","fromtitle":"Bioequivalence","byteoffset":12240,"anchor":"References"},{"toclevel":1,"level":"2","line":"External links","number":"6","index":"10","fromtitle":"Bioequivalence","byteoffset":12270,"anchor":"External_links"}],"parsewarnings":[],"displaytitle":"Bioequivalence","iwlinks":[],"properties":[{"name":"wikibase_item","*":"Q864940"}]}}